Travis Wilson

Travis Wilson is an investment partner at Gurnet Point Capital, a global healthcare fund focused on growth equity and venture opportunities in the life sciences. Previously, he was the President and CEO of Stealth BioTherapeutics, a late-stage clinical biotechnology company developing therapies to treat mitochondrial dysfunction in common and rare diseases.

Travis has extensive experience in leading biotechnology companies and ventures to invest, heading transactions from seed investments to commercial assets. For more than a decade, he was a member of the investment team at Morningside Ventures, an international firm dedicated to life science and technology startups. With Morningside, he worked on multiple financings, including several public and private biotechnology companies such as Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: ADRO), and Argos (NASDAQ: ARGS).

Travis also served as a director and board member for nonclinical and clinical-stage companies, providing operational and management support to a portfolio of companies developing technologies across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell therapy, and ophthalmology. He has lectured extensively on life science investing and management and is a long-time supporter of patient-advocacy groups including the United Mitochondrial Disease Foundation and the National Organization for Rare Disorders. Travis holds a law degree and a chemical engineering degree, both from the University of Wisconsin.